Zobrazeno 1 - 10
of 146
pro vyhledávání: '"ASSOCIATION HFA"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
JACC-Heart Failure. 7(1):13-21
OBJECTIVES This study investigated adherence to drug therapy guidelines in heart failure (HF) with reduced left-ventricular ejection fraction (LVEF) ofBACKGROUND Despite previous surveys of HF, important uncertainties remain regarding guideline adher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od________83::3950ac2d4571a0cd30c6d8aaef1e3ef5
https://cris.maastrichtuniversity.nl/en/publications/be6548d2-dc3c-4368-8675-94c4b22eafd4
https://cris.maastrichtuniversity.nl/en/publications/be6548d2-dc3c-4368-8675-94c4b22eafd4
Autor:
Tahar Chouihed, Pierre Nazeyrollas, Bruno Maillier, James L. Januzzi, Nicolas Girerd, Alexandre Mebazaa, Pascal Bilbault, William T. Abraham, François Braun, Stefano Coiro, Ludivine Fillieux, David Kenizou, Gérard Roul, Faiez Zannad, Marie-France Seronde, Patrick Rossignol, Laurent Sebbag
Publikováno v:
JACC: Heart Failure
JACC: Heart Failure, Elsevier/American College of Cardiology, 2018, 6 (4), pp.273-285. ⟨10.1016/j.jchf.2017.09.023⟩
JACC: Heart Failure, Elsevier/American College of Cardiology, 2018, 6 (4), pp.273-285. ⟨10.1016/j.jchf.2017.09.023⟩
International audience; Congestion is one of the main predictors of poor patient outcome in patients with heart failure. However, congestion is difficult to assess, especially when symptoms are mild. Although numerous clinical scores, imaging tools,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0041ecc6ebc7dda154574a2eb9e0ca52
https://doi.org/10.1016/j.jchf.2017.09.023
https://doi.org/10.1016/j.jchf.2017.09.023
Autor:
Adriaan A. Voors, Hans L. Hillege, Wouter Ouwerkerk, Marco Metra, Gerjan Navis, Peter van der Meer, Aeilko H. Zwinderman, Gerasimos Filippatos, Nilesh J. Samani, Piotr Ponikowski, Pim van der Harst, Chim C. Lang, Dirk J. van Veldhuisen, Stefan D. Anker, Martin H. de Borst, Kevin Damman, Leong L. Ng, Jozine M. ter Maaten, John G.F. Cleland, Kenneth Dickstein, Faiez Zannad
Publikováno v:
International journal of cardiology, 253, 84-90. Elsevier Ireland Ltd
International Journal of Cardiology, 253, 84-90. ELSEVIER IRELAND LTD
International Journal of Cardiology, 253, 84-90. ELSEVIER IRELAND LTD
Background: Fibroblast growth factor (FGF) 23 is a hormone that increases urinary phosphate excretion and regulates renal sodium reabsorption and plasma volume. We studied the role of plasma FGF23 in therapy optimization and outcomes in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99aee8297a61e68012e4ec1151a2ba08
https://doi.org/10.1016/j.ijcard.2017.10.010
https://doi.org/10.1016/j.ijcard.2017.10.010
Publikováno v:
Journal of the American College of Cardiology. 71(4):386-398
BACKGROUND Heart failure guidelines recommend up-titration of angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) to doses used in randomized clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___00893::728188752b635432ad4fb21395321519
https://hdl.handle.net/11370/360d34a1-2c36-4973-8548-1ee7dac3a602
https://hdl.handle.net/11370/360d34a1-2c36-4973-8548-1ee7dac3a602
Publikováno v:
European Journal of Heart Failure. 20(1):89-96
AIMS: Previous studies have identified candidate circulating microRNAs (circmiRs) as biomarkers for heart failure (HF) using relatively insensitive arrays, validated in small cohorts. The present study used RNA sequencing to identify novel candidate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___01423::389189cfaf5d503c202e08b46da626ef
https://research.rug.nl/en/publications/f1fcc818-d104-417f-8b2a-c6435c4c1e64
https://research.rug.nl/en/publications/f1fcc818-d104-417f-8b2a-c6435c4c1e64
Publikováno v:
European Journal of Heart Failure. 19(12):1569-1573
The 2016 European Society of Cardiology heart failure guidelines introduced the term 'heart failure with mid-range ejection fraction' (HFmrEF) to refer to patients with heart failure and a mildly reduced ejection fraction of 40-49%. About 20% of hear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___01423::e0817beedf84071500206e3239053644
https://research.rug.nl/en/publications/476592cf-c644-4c15-86de-5856ae43d888
https://research.rug.nl/en/publications/476592cf-c644-4c15-86de-5856ae43d888
Publikováno v:
European Journal of Heart Failure. 19(11):1495-1503
Aims This randomized, double-blind, placebo-controlled trial assessed whether heart rate (HR) reduction with ivabradine improves cardiac function in heart failure with preserved ejection fraction (HFpEF).Methods and results The prEserveD left ventric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___01423::681024f42798c4fb85666c6f8713653a
https://doi.org/10.1002/ejhf.876
https://doi.org/10.1002/ejhf.876
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction
Publikováno v:
European Journal of Heart Failure. 19(10):1284-1293
Aims: Mineralocorticoid receptor antagonists (MRAs) are recommended (unless contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). However, MRAs are still largely underused in routine clinical practice. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___00893::60acf08e7fab3b89f2df0e8a03fbfa75
https://hdl.handle.net/11370/65e93642-6f6f-4817-96b7-f1f067ea5db1
https://hdl.handle.net/11370/65e93642-6f6f-4817-96b7-f1f067ea5db1